Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-10-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
中瑞世联资产评估集团有限公司关于深圳证券交易所《关于对盈康生命科技股份有限公司的重组问询函》的回复（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed response to an inquiry from the Shenzhen Stock Exchange regarding a restructuring transaction involving Yingkang Life Technology Co., Ltd. It includes extensive financial forecasts, valuation justifications, transaction pricing, and performance commitments related to the acquisition of a target company (Suzhou Guangci). The content focuses on the fairness of the transaction price, net asset valuation, profit forecasts, and payment terms for the equity transfer. The document is not a full annual or interim report, nor is it a simple announcement or certification. It is a detailed disclosure related to a corporate restructuring transaction, specifically addressing regulatory inquiries about the transaction. This fits the category of a Regulatory Filing (RNS) because it is a regulatory response document that does not constitute a full financial report but provides detailed information about a restructuring transaction and related financial data. It is not a merger proxy statement or tender offer filing (MA or TAR), but a regulatory inquiry response. Therefore, the best classification is Regulatory Filings (RNS).
2021-10-21 Chinese
国泰君安证券股份有限公司关于公司重大资产购买暨关联交易之独立财务顾问报告（五次修订稿）
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a major asset purchase and related party transaction involving Yingkang Life Technology Co., Ltd. It includes detailed sections such as transaction overview, asset evaluation, legal opinions, audit reports, and compliance with regulatory requirements. The document references specific regulatory frameworks for major asset restructurings and includes extensive financial and legal analysis. This type of document is typical of an independent financial advisor report prepared for a significant asset acquisition and related party transaction, which is a specialized financial advisory report rather than a general annual report or earnings release. It is not a simple announcement or certification but a comprehensive advisory report. Therefore, the most appropriate classification is Audit Report / Information (AR), as it is a standalone detailed advisory and audit-related report on a major transaction, distinct from full annual reports or other categories. H1 2021
2021-10-21 Chinese
国泰君安证券股份有限公司关于公司关于深圳证券交易所《关于对盈康生命科技股份有限公司的重组问询函》回复之核查意见（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding a major asset purchase and related party transaction involving Yingkang Life Technology Co., Ltd. It includes extensive financial data, profit forecasts for 2021-2025, detailed explanations of revenue and cost projections, business and operational analysis, and valuation rationales. The document references a restructuring inquiry letter from the Shenzhen Stock Exchange and provides a comprehensive response with financial analysis and fairness opinions. The content is focused on a major asset acquisition transaction, including valuation, pricing fairness, and shareholder interest protection. This aligns with the category of Capital/Financing Update (CAP), as it deals with financing activities and capital structure changes related to a significant asset purchase and restructuring. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-10-21 Chinese
关于深圳证券交易所创业板非许可类重组问询函【2021】第13号回复的公告（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed announcement and response to an inquiry letter from the Shenzhen Stock Exchange regarding a non-permitted restructuring involving a significant asset purchase and related party transaction by Yingkang Life Technology Co., Ltd. It includes extensive financial forecasts, valuation rationales, transaction pricing, and adjustments to the restructuring plan. The content focuses on the explanation and justification of the restructuring transaction, including financial projections, valuation, fairness, and shareholder interest protection. It is not a full annual or interim report, nor is it a simple announcement or certification. It is a regulatory disclosure related to a restructuring transaction inquiry and response, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like M&A filings or capital updates, given the nature of the inquiry and response format.
2021-10-21 Chinese
关于本次重组方案调整不构成重大调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 盈康生命科技股份有限公司 regarding adjustments to a major asset restructuring plan. It details changes in the restructuring scheme, including performance commitment periods and payment methods for equity transfer consideration. The document references multiple board meetings approving these adjustments and explicitly states that the adjustments do not constitute a major change to the restructuring plan. The content focuses on the restructuring transaction details and related agreements, not on the full asset purchase report itself. The document length is about 5380 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial statement or comprehensive analysis typical of an Annual Report or Interim Report. The document is not a proxy statement, voting result, or management change announcement. It is a regulatory announcement about a capital restructuring transaction update, fitting best under Capital/Financing Update (CAP).
2021-10-18 Chinese
独立董事关于第五届董事会第十五次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting regarding a major asset acquisition and related transactions. It discusses the approval of related proposals, compliance with laws and regulations, and protection of shareholder interests. The content focuses on governance and approval of a significant transaction rather than presenting financial statements or detailed financial results. It is not a full annual or interim report, nor an earnings release or audit report. The document is a formal opinion related to board/management decisions on a major asset acquisition and related governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1467 characters), and it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS.
2021-10-18 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.